Fierce Pharma
JULY 6, 2023
After becoming chairman of the powerful Senate Health, Education, Labor and Pensions Committee earlier this year, Sen. | After becoming chairman of the powerful Senate Health, Education, Labor and Pensions Committee earlier this year, Sen. Bernie Sanders, I-Vermont—a longtime opponent of Big Pharma—has become even more ubiquitous in his efforts to reduce drug prices.
Pharmacy Times
JULY 6, 2023
The benefits of the survey can stretch beyond assessing the parental acceptability of mental health screenings in children and can suggest areas of optimization in providing these screenings more widely and effectively in the future.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JULY 6, 2023
Less than two months into its "Pivot to Growth" strategy under a new CEO, Israeli-American generics giant Teva Pharmaceutical could be weighing a major shake-up of its key drug ingredients business | Teva is looking at strategic options for its active pharmaceutical ingredient unit, with a potential sale on the table, BNN Bloomberg and Benzinga have reported.
Pharmacy Times
JULY 6, 2023
Lecanemab-irmb is the first amyloid beta-directed antibody to be converted from an accelerated approval to a traditional approval for the treatment of Alzheimer disease.
Speaker: Chris Antypas and Josh Halladay
Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.
Fierce Pharma
JULY 6, 2023
It’s official: Roughly half a year after the FDA granted an accelerated nod to Eisai and Biogen’s new Alzheimer’s disease med lecanemab, the companies have converted that green light into a full-fl | With a full approval in hand, Leqembi has become the first treatment shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease under the FDA's traditional approval pathway.
Pharmacy Times
JULY 6, 2023
mRNA-1345 is a vaccine indicated for the prevention of respiratory syncytial virus-associated lower respiratory tract disease and acute respiratory disease.
Pharmacy Technician Pulse brings together the best content for pharmacy technicians from the widest variety of industry thought leaders.
Pharmacy Times
JULY 6, 2023
COVID-19 is helping to shape current pharmacy practice, including increased vaccinations, access to care, and better interactions with patients.
Fierce Healthcare
JULY 6, 2023
Stanford Medicine and the Department of Veterans Affairs (VA) unveiled plans Friday to collaborate on a project that will bring a new National Cancer Institute-designated joint cancer care and rese | Stanford Medicine and the VA unveiled plans on Friday to collaborate on a project that will bring a new National Cancer Institute-designated joint cancer care and research center to the VA Palo Alto campus.
Pharmacy Times
JULY 6, 2023
Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.
Fierce Pharma
JULY 6, 2023
GSK’s Cabenuva made history in 2020 as the world’s firs | GSK's long-acting Cabenuva is currently approved only as a switch therapy for patients who already have undetectable HIV levels in the blood. Trying to reach some tough populations who have difficulty adhering to existing daily oral therapies, GSK is getting creative.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharmacy Times
JULY 6, 2023
Despite recommendations for adults to receive lung cancer screenings, rates have remained low compared with other cancer screening programs.
STAT
JULY 6, 2023
The STAT Diversity and Inclusion Committee is proud to present STAT’s inaugural Diversity and Inclusion Report. Here, we share the self-reported gender and racial/ethnic demographics of our staff from STAT’s inception in 2015 through 2022. This report presents an opportunity to reaffirm STAT’s commitment to becoming the most diverse media company covering the life sciences and health care.
Drug Topics
JULY 6, 2023
Researchers concluded that older patients with stable MS can stop taking disease-modifying therapy because risk of relapse is so small.
STAT
JULY 6, 2023
When then-Vice President Biden launched the Cancer Moonshot in 2016, there was reason to be optimistic. Decades of rigorous science had transformed many cancers from a death sentence to a manageable chronic disease. New treatment advances — including gene and cell therapies and immunotherapies — were showing stunning results. With support from the biopharmaceutical industry and the help of smart government policies, ending cancer was, and is, an achievable goal.
Advertisement
Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.
Fierce Pharma
JULY 6, 2023
In this episode of "The Top Line," we talk with ViiV’s head of R&D, Dr. Kimberly Smith, about new HIV therapies. | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines.
Pharmacy Times
JULY 6, 2023
The safety and efficacy of long-term benzodiazepine use beyond the recommended timeframe is not well understood.
Fierce Pharma
JULY 6, 2023
During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company’s biggest issue: underutilization of existing infrastructure. | During the first earnings call Brent Saunders led since his return at Bausch + Lomb, the CEO laid out what he believes is the company’s biggest issue: underutilization of existing infrastructure.
STAT
JULY 6, 2023
Traumatic brain injury multiplies the risk of major depression eightfold. While the emotional trauma of whatever caused such deep damage may be understandable, from a blast in a war zone to a blow on the playing field, there’s a physiological component, too, that neuroscientists have long suspected but have been unable to identify. “As clinicians, a lot of us had a gut feeling that [TBI-associated depression] is a different disease,” said Shan Siddiqi, a Harvard Medical Scho
Fierce Healthcare
JULY 6, 2023
Maternal death rates more than doubled over the last two decades, with Black, American Indian and Native Alaskan women being particularly vulnerable to this trend, according to a
STAT
JULY 6, 2023
The Food and Drug Administration on Thursday granted full approval to the first therapy for Alzheimer’s disease clearly shown to slow the cognitive decline associated with the disease — a milestone in treatment, even if the benefits are modest. The drug, called Leqembi , was developed by Eisai , the Japanese pharmaceutical company, and sold in partnership with Biogen.
PharmExec
JULY 6, 2023
Senior editor Fran Pollaro chats with Sharlene Jenner, vice president of engagement strategy, Abelson Taylor about the transformative impact and ethical considerations of AI in the pharmaceutical industry, emphasizing its potential in data analysis and marketing, while also highlighting the pioneering work of AI companies in advancing drug discovery.
STAT
JULY 6, 2023
The partnership that would shape Eli Lilly into one of the biggest success stories in the pharmaceutical industry began with conversations around a relatively minor acquisition. At the time, David Ricks was running Lilly’s U.S. business and was part of the team charged with evaluating Avid Radiopharmaceuticals, which Lilly would go on to purchase in 2010 for a paltry $300 million — couch change for a multibillion-dollar firm.
pharmaphorum
JULY 6, 2023
In our penultimate video from ASCO 2023, Editor in Chief Jonah Comstock touches base with Biofourmis Chief Operating Officer Jaydev Thakkar. Biofourmis works with pharma on accelerating drug development and with post-market monitoring of approved drugs.
STAT
JULY 6, 2023
Drinking water from nearly half of U.S. faucets likely contains “forever chemicals” that may cause cancer and other health problems, according to a government study released Wednesday. The synthetic compounds known collectively as PFAS are contaminating drinking water to varying extents in large cities and small towns — and in private wells and public systems, the U.S.
Outsourcing Pharma
JULY 6, 2023
This yearâs CPHI South East Asia is expecting a surge in international partnering with organizers expecting a record attendance of 8,000 visitors including a significant number from overseas â doubling last yearâs figures.
STAT
JULY 6, 2023
At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits. The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health.
pharmaphorum
JULY 6, 2023
In this episode of the pharmaphorum podcast, brought to you by Advanced Clinical, Advanced Clinical’s SVP Strategic Resourcing Steve Mattas and VP of Global Talent and Client Delivery James Nyssen speak with host Jonah Comstock about findings from a recent report by their company on the current personnel dynamics in pharma.
STAT
JULY 6, 2023
WASHINGTON – If you live in this city, you’re probably awash in pharmacy benefit manager ads — whether you’re listening to an NPR podcast, reading the New York Times, streaming “Yellowstone,” or watching the U.S. Open Golf Championships. It doesn’t matter if it’s 5 a.m., primetime, or 11 p.m.; in between ads for dog joint supplements and the “Barbie” movie, you will inevitably learn about these middlemen of the prescription dr
European Pharmaceutical Review
JULY 6, 2023
BioNTech SE and the UK government have jointly agreed to provide up to 10,000 patients with personalised cancer immunotherapies by 2030. Signing of this agreement builds on a memorandum of understanding signed in January. The partnership will provide cancer patients with improved access to the latest cancer trials and therapies currently being developed.
STAT
JULY 6, 2023
The trade group for generic drug companies has filed a lawsuit alleging a Minnesota law that is designed to provide transparency into prescription drug pricing is unconstitutional, the latest effort to push back against states attempting to lower the cost of medicines. In its lawsuit , the Association for Accessible Medicines claimed the law is an “unconstitutional overreach,” because it gives the state the power to regulate interstate commerce and apply Minnesota law to prices cha
Drug Store News
JULY 6, 2023
The sister companies have expanded their suite of clinical management and stop-loss solutions to help self-funded plans maintain affordable pharmacy benefits.
Pharmaceutical Technology
JULY 6, 2023
Lifera, Arabio and Sanofi have signed a memorandum of understanding (MOU) to bolster manufacturing of vaccines in Saudi Arabia.
Drug Store News
JULY 6, 2023
HRG reviewed 37 products in the health category, 43 in the wellness sector and 52 items in the beauty aisle to see which ones stood out as Products to Watch.
Drug Topics
JULY 6, 2023
The Humira biosimilar is a tumor necrosis factor (TNF) blocker and was approved by the FDA in 2021.
Expert insights. Personalized for you.
145 
Let's personalize your content